Literature DB >> 2678949

The relationship between MHC antigen expression and metastasis.

J Gopas1, B Rager-Zisman, M Bar-Eli, G J Hämmerling, S Segal.   

Abstract

From the studies summarized here a complex picture of the role played by MHC products in determining tumorigenicity and metastasis is emerging. In order to be able to understand this relationship better, it is necessary to consider several factors. 1. Each tumor system or neoplastic tissue is unique, and its behavior reflects the influence of cell-specific characteristics, as well as its ability to modulate other cells and tissues--including cells belonging to the immune system--and also to be modulated by other cells and soluble factors. 2. Since metastasis formation is a multistep process in which only small subpopulations of tumor cells with complex and defined phenotypes are able to colonize secondary tissues, elimination of even one single phenotypic component of this structured process can easily reverse the metastatic capacity of the cells. Acquisition of metastatic ability, on the other hand, would be a more difficult task, since any new characteristic expressed by the cells or induced experimentally, such as gene transfection or results of IFN treatment, must be expressed in a temporal manner and in concert with other cellular characteristics. Therefore, an experimental protocol measuring a specific element in determining metastasis can easily produce conflicting results, depending on the type of cells and genetic background of the host studied. 3. The level of specific MHC products on tumor cells is one among many other cell characteristics that may determine the metastatic potential of cells. Moreover, each of the class 1 MHC products, and the relationship among them, including other than the classical K, L, or D products (Brickell et al., 1983), should be regarded as independent entities, with possible different regulatory roles in cell-cell recognition, in a general sense, which may be involved in determining invasiveness and homing as well as recognition by the immune system. 4. Both specific T-cell and nonspecific natural mediated immunity (which is much less understood) are involved in the selection of the metastatic cell population. 5. Immunogenicity of tumors is not necessarily determined by high levels of MHC antigen expression; it is also dependent on the level of TSA. Thus, immunoselection mediated by T lymphocytes during metastasis formation could be directed against both MHC and TSA antigens. Therefore, low expression of MHC antigens by metastatic cells as a result of immunoselection is not always observed.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2678949     DOI: 10.1016/s0065-230x(08)60280-8

Source DB:  PubMed          Journal:  Adv Cancer Res        ISSN: 0065-230X            Impact factor:   6.242


  15 in total

Review 1.  Role of major histocompatibility complex class-I molecules in tumor rejection. New insights from studies with synthetic peptides and transgenic mice.

Authors:  P Höglund; H G Ljunggren; K Kärre; G Jay
Journal:  Immunol Res       Date:  1990       Impact factor: 2.829

2.  Possible role of Abb gene in mouse resistance to EL4 metastases.

Authors:  O S Egorov; Y Liu; I K Egorov
Journal:  Immunogenetics       Date:  1992       Impact factor: 2.846

3.  Altered binding of regulatory factors to HLA class I enhancer sequence in human tumor cell lines lacking class I antigen expression.

Authors:  O Blanchet; J F Bourge; H Zinszner; A Israel; P Kourilsky; J Dausset; L Degos; P Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1992-04-15       Impact factor: 11.205

4.  Biological properties associated with the enhanced lung-colonizing potential in a B16 murine melanoma line grown in a medium conditioned by syngeneic Corynebacterium parvum-elicited macrophages.

Authors:  L Calorini; A Mannini; F Bianchini; G Mugnai; M Balzi; A Becciolini; S Ruggieri
Journal:  Clin Exp Metastasis       Date:  1999       Impact factor: 5.150

5.  Expression of beta 2-microglobulin by human benign and malignant mesenchymal and neurogenic tumours.

Authors:  B L Petersen; O Braendstrup
Journal:  Int J Exp Pathol       Date:  1993-08       Impact factor: 1.925

6.  Human hepatoma cells expressing MHC antigens display accessory cell function: dependence on LFA-1/ICAM-1 interaction.

Authors:  M Paroli; G Carloni; A Franco; G De Petrillo; E Alfani; A Perrone; V Barnaba
Journal:  Immunology       Date:  1994-06       Impact factor: 7.397

7.  Persistent measles virus infection enhances major histocompatibility complex class I expression and immunogenicity of murine neuroblastoma cells.

Authors:  J Gopas; D Itzhaky; Y Segev; S Salzberg; B Trink; N Isakov; B Rager-Zisman
Journal:  Cancer Immunol Immunother       Date:  1992       Impact factor: 6.968

8.  Tumorigenicity of mouse T lymphoma cells is controlled by the level of major histocompatibility complex class I H-2Kk antigens.

Authors:  T VandenDriessche; M Bakkus; D Toussaint-Demylle; K Thielemans; H Verschueren; P De Baetselier
Journal:  Clin Exp Metastasis       Date:  1994-01       Impact factor: 5.150

9.  Expression of MHC class I and class II antigens in primary breast carcinomas and synchronous nodal metastases.

Authors:  A Maiorana; A M Cesinaro; R A Fano; G Collina
Journal:  Clin Exp Metastasis       Date:  1995-01       Impact factor: 5.150

10.  Adenovirus 12-mediated down-regulation of the major histocompatibility complex (MHC) class I promoter: identification of a negative regulatory element responsive to Ad12 E1A.

Authors:  J L Proffitt; E Sharma; G E Blair
Journal:  Nucleic Acids Res       Date:  1994-11-11       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.